Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):482–486. doi: 10.1038/bjc.1994.87

Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.

V Rantanen 1, S Grénman 1, J Kulmala 1, R Grénman 1
PMCID: PMC1968845  PMID: 8123477

Abstract

Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two long-established (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B, UT-EC-3) using the 96-well-plate clonogenic assay. This assay has proven to be suitable for testing chemosensitivity of both adenocarcinoma and squamous cell carcinoma. The chemosensitivity was expressed as an IC50 value, the drug concentration causing 50% inhibition of clonogenic survival. IC50 values were obtained from dose-response curves after fitting the data by the linear quadratic equation, F = exp[-(alpha D + beta D2)]. The IC50 values of the two platinum derivatives varied considerably. The values for cisplatin varied between 0.022 microgram ml-1 and 0.56 microgram ml-1 and the corresponding values for carboplatin were 0.096-1.20 microgram ml-1. The range of the ratios between carboplatin IC50 and cisplatin IC50, from 1.5:1 to 4.4:1, was rather narrow. However, no constant ratio between carboplatin IC50 and cisplatin IC50 could be detected. The equivalent doses with regard to efficacy of these two platinum analogues remain to be determined.

Full text

PDF
482

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Choi K. N., Rotman M., Aziz H., Potters L., Stark R., Rosenthal J. C. Locally advanced paranasal sinus and nasopharynx tumors treated with hyperfractionated radiation and concomitant infusion cisplatin. Cancer. 1991 Jun 1;67(11):2748–2752. doi: 10.1002/1097-0142(19910601)67:11<2748::aid-cncr2820671106>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  2. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403–426. doi: 10.1016/0360-3016(87)90015-0. [DOI] [PubMed] [Google Scholar]
  3. Dittrich C., Sevelda P., Baur M., Marth C., Hudec M., Vavra N., Grunt T., Fazeny B., Salzer H. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer. 1993 May 15;71(10):3082–3090. doi: 10.1002/1097-0142(19930515)71:10<3082::aid-cncr2820711031>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  4. Dunton C. J., Pfeifer S. M., Braitman L. E., Morgan M. A., Carlson J. A., Mikuta J. J. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 1991 May;41(2):113–116. doi: 10.1016/0090-8258(91)90268-a. [DOI] [PubMed] [Google Scholar]
  5. Fanning J., Biddle W. C., Goldrosen M., Crickard K., Crickard U., Piver M. S., Foon K. A. Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol. 1990 Nov;39(2):119–122. doi: 10.1016/0090-8258(90)90416-i. [DOI] [PubMed] [Google Scholar]
  6. Grenman R., Burk D., Virolainen E., Buick R. N., Church J., Schwartz D. R., Carey T. E. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer. 1989 Jul 15;44(1):131–136. doi: 10.1002/ijc.2910440123. [DOI] [PubMed] [Google Scholar]
  7. Grenman R., Burk D., Virolainen E., Wagner J. G., Lichter A. S., Carey T. E. Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1988 Apr;114(4):427–431. doi: 10.1001/archotol.1988.01860160071024. [DOI] [PubMed] [Google Scholar]
  8. Grenman S. E., Van Dyke D. L., Worsham M. J., del Rosario F., Roberts J. A., McClatchey K. D., Schwartz D. R., Babu V. R., Carey T. E. UM-EC-1, a new hypodiploid human cell line derived from a poorly differentiated endometrial cancer. Cancer Res. 1988 Apr 1;48(7):1864–1873. [PubMed] [Google Scholar]
  9. Grenman S. E., Worsham M. J., Van Dyke D. L., England B., McClatchey K. D., Babu V. R., Roberts J. A., Mäenpä J., Carey T. E. Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gynecol Oncol. 1990 May;37(2):188–199. doi: 10.1016/0090-8258(90)90332-f. [DOI] [PubMed] [Google Scholar]
  10. Grénman R., Carey T. E., McClatchey K. D., Wagner J. G., Pekkola-Heino K., Schwartz D. R., Wolf G. T., Lacivita L. P., Ho L., Baker S. R. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer. 1991 Jun 1;67(11):2741–2747. doi: 10.1002/1097-0142(19910601)67:11<2741::aid-cncr2820671105>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  11. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hoffman M. S., Roberts W. S., Cavanagh D., Praphat H., Solomon P., Lyman G. H. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. Gynecol Oncol. 1989 Oct;35(1):75–77. doi: 10.1016/0090-8258(89)90016-4. [DOI] [PubMed] [Google Scholar]
  13. Jacobs M. C., Eisenberger M., Oh M. C., Sinibaldi V., Gray W., Elias G., Salazar O. M. Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: a phase I-II study. Int J Radiat Oncol Biol Phys. 1989 Aug;17(2):361–363. doi: 10.1016/0360-3016(89)90451-3. [DOI] [PubMed] [Google Scholar]
  14. Jones C. M., 3rd, Welander C. E., Berens M. E., Homesley H. D. In vitro growth characteristics and chemosensitivities of endometrial cancer using a soft agar clonogenic assay. Obstet Gynecol. 1987 Feb;69(2):237–241. [PubMed] [Google Scholar]
  15. Kelland L. R., Tonkin K. S. In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1211–1218. doi: 10.1016/0277-5379(89)90417-3. [DOI] [PubMed] [Google Scholar]
  16. Litterst C. L., Gram T. E., Dedrick R. L., Leroy A. F., Guarino A. M. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res. 1976 Jul;36(7 Pt 1):2340–2344. [PubMed] [Google Scholar]
  17. Nguyen H. N., Sevin B. U., Averette H. E., Gottlieb C., Perras J., Donato D., Penalver M. Radiosensitization of uterine cancer cell lines by cytotoxic agents. Gynecol Oncol. 1993 Jan;48(1):16–22. doi: 10.1006/gyno.1993.1004. [DOI] [PubMed] [Google Scholar]
  18. Nguyen H. N., Sevin B. U., Averette H. E., Perras J., Donato D., Penalver M. Comparative evaluation of single and combination chemotherapy in uterine cancer cell lines. Gynecol Oncol. 1991 Sep;42(3):227–232. doi: 10.1016/0090-8258(91)90350-e. [DOI] [PubMed] [Google Scholar]
  19. Pekkola-Heino K., Kulmala J., Grenman R. Carboplatin-radiation interaction in squamous cell carcinoma cell lines. Arch Otolaryngol Head Neck Surg. 1992 Dec;118(12):1312–1315. doi: 10.1001/archotol.1992.01880120038007. [DOI] [PubMed] [Google Scholar]
  20. Pekkola-Heino K., Kulmala J., Grenman R. Sublethal damage repair in squamous cell carcinoma cell lines. Head Neck. 1992 May-Jun;14(3):196–199. doi: 10.1002/hed.2880140306. [DOI] [PubMed] [Google Scholar]
  21. Pekkola-Heino K., Kulmala J., Grenman S., Carey T. E., Grenman R. Radiation response of vulvar squamous cell carcinoma (UM-SCV-1A, UM-SCV-1B, UM-SCV-2, and A-431) cells in vitro. Cancer Res. 1989 Sep 1;49(17):4876–4878. [PubMed] [Google Scholar]
  22. Pekkola-Heino K., Kulmala J., Klemi P., Lakkala T., Aitasalo K., Joensuu H., Grenman R. Effects of radiation fractionation on four squamous cell carcinoma lines with dissimilar inherent radiation sensitivity. J Cancer Res Clin Oncol. 1991;117(6):597–602. doi: 10.1007/BF01613295. [DOI] [PubMed] [Google Scholar]
  23. Rantanen V., Grénman S., Kulmala J., Salmi T., Grénman R. Radiation sensitivity of endometrial carcinoma in vitro. Gynecol Oncol. 1992 Mar;44(3):217–222. doi: 10.1016/0090-8258(92)90045-k. [DOI] [PubMed] [Google Scholar]
  24. Richardson G. S., Dickersin G. R., Atkins L., MacLaughlin D. T., Raam S., Merk L. P., Bradley F. M. KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol. 1984 Feb;17(2):213–230. doi: 10.1016/0090-8258(84)90080-5. [DOI] [PubMed] [Google Scholar]
  25. Takahashi H., Sasaki Y., Saijo N., Sakurai M., Nakano H., Nakagawa K., Hoshi A., Jett J. R., Hong W. S. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin. Cancer Chemother Pharmacol. 1987;19(3):197–200. doi: 10.1007/BF00252972. [DOI] [PubMed] [Google Scholar]
  26. Terheggen P. M., Begg A. C., Emondt J. Y., Dubbelman R., Floot B. G., den Engelse L. Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. Br J Cancer. 1991 Feb;63(2):195–200. doi: 10.1038/bjc.1991.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Terheggen P. M., Dijkman R., Begg A. C., Dubbelman R., Floot B. G., Hart A. A., den Engelse L. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res. 1988 Oct 1;48(19):5597–5603. [PubMed] [Google Scholar]
  28. Terheggen P. M., Emondt J. Y., Floot B. G., Dijkman R., Schrier P. I., den Engelse L., Begg A. C. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 1990 Jun 15;50(12):3556–3561. [PubMed] [Google Scholar]
  29. Thigpen T., Vance R., Lambuth B., Balducci L., Khansur T., Blessing J., McGehee R. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer. 1987 Oct 15;60(8 Suppl):2104–2116. doi: 10.1002/1097-0142(19901015)60:8+<2104::aid-cncr2820601524>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  30. Way D. L., Grosso D. S., Davis J. R., Surwit E. A., Christian C. D. Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro. 1983 Mar;19(3 Pt 1):147–158. doi: 10.1007/BF02618053. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES